CN112543768B - 修饰结合分子以最小化预先存在的相互作用 - Google Patents

修饰结合分子以最小化预先存在的相互作用 Download PDF

Info

Publication number
CN112543768B
CN112543768B CN201980042886.7A CN201980042886A CN112543768B CN 112543768 B CN112543768 B CN 112543768B CN 201980042886 A CN201980042886 A CN 201980042886A CN 112543768 B CN112543768 B CN 112543768B
Authority
CN
China
Prior art keywords
seq
sequence
antibody
amino acid
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980042886.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN112543768A (zh
Inventor
G·萨姆纳
陈继华
M·帕特里奇
A·托里
M·拉加亚克沙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN112543768A publication Critical patent/CN112543768A/zh
Application granted granted Critical
Publication of CN112543768B publication Critical patent/CN112543768B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980042886.7A 2018-07-10 2019-07-10 修饰结合分子以最小化预先存在的相互作用 Active CN112543768B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695988P 2018-07-10 2018-07-10
US62/695988 2018-07-10
PCT/US2019/041203 WO2020014358A1 (en) 2018-07-10 2019-07-10 Modifying binding molecules to minimize pre-existing interactions

Publications (2)

Publication Number Publication Date
CN112543768A CN112543768A (zh) 2021-03-23
CN112543768B true CN112543768B (zh) 2024-05-03

Family

ID=67544330

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980042886.7A Active CN112543768B (zh) 2018-07-10 2019-07-10 修饰结合分子以最小化预先存在的相互作用

Country Status (16)

Country Link
US (2) US11448651B2 (https=)
EP (1) EP3820891A1 (https=)
JP (2) JP7665339B2 (https=)
KR (1) KR102938177B1 (https=)
CN (1) CN112543768B (https=)
AR (1) AR115730A1 (https=)
AU (1) AU2019302642B2 (https=)
BR (1) BR112020026784A2 (https=)
CA (1) CA3104873A1 (https=)
EA (1) EA202190228A1 (https=)
IL (2) IL316308A (https=)
MX (2) MX2021000239A (https=)
MY (1) MY202673A (https=)
SG (1) SG11202012835RA (https=)
TW (2) TW202428612A (https=)
WO (1) WO2020014358A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019302642B2 (en) 2018-07-10 2025-10-30 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
US20260008857A1 (en) * 2024-06-13 2026-01-08 Flagship Pioneering Innovations Vi, Llc Antigen Binding Molecules Targeting Interleukine-4 Receptor Subunit Alpha (IL-4Ra)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
WO2010042904A2 (en) * 2008-10-10 2010-04-15 Trubion Pharmaceuticals, Inc. Tcr complex immunotherapeutics
CN103833855A (zh) * 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
CN103917557A (zh) * 2011-08-17 2014-07-09 葛兰素集团有限公司 具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体
CN105377894A (zh) * 2013-06-04 2016-03-02 瑞泽恩制药公司 以il-4r抑制剂治疗过敏症及强化过敏原特异性免疫治疗的方法
CN106573074A (zh) * 2014-06-02 2017-04-19 里珍纳龙药品有限公司 生物活性分子偶联物、试剂和制备方法及其治疗用途
WO2018091580A1 (en) * 2016-11-18 2018-05-24 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2644663A1 (en) 2006-03-23 2007-09-27 Kirin Pharma Kabushiki Kaisha Agonist antibody to human thrombopoietin receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
AU2008348252A1 (en) 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
CA2741114A1 (en) 2008-10-24 2010-04-29 Cornelis Lammert Verweij Biomarkers for predicting the development of chronic autoimmune diseases
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
WO2010122148A1 (en) 2009-04-24 2010-10-28 Boehringer Ingelheim International Gmbh An improved antibody domain and antibody fragments and antibodies based thereon
WO2011074965A1 (en) 2009-12-17 2011-06-23 Stichting Sanquin Bloedvoorziening Methods and means for counteracting an activity of an fc domain
WO2012166588A2 (en) 2011-06-01 2012-12-06 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CN117442748A (zh) 2014-10-02 2024-01-26 希望之城公司 多价中间表位、中间表位结合抗体及其用途
BR112017004810A2 (pt) 2014-11-05 2017-12-12 Hoffmann La Roche imunoensaio
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
AU2016344665C1 (en) * 2015-10-29 2023-07-27 F. Hoffmann-La Roche Ag Anti-variant Fc-region antibodies and methods of use
US20170137535A1 (en) 2015-10-30 2017-05-18 Genentech, Inc. Anti-factor d antibody formulations
BR112019004733A2 (pt) 2016-09-19 2019-05-28 Celgene Corp métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
WO2019101863A1 (en) 2017-11-22 2019-05-31 Vacara Ab Antibodies to citrullinated proteins
AU2019302642B2 (en) 2018-07-10 2025-10-30 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
WO2020246891A1 (en) 2019-06-07 2020-12-10 Sanquin Innovatie B.V. Methods and compounds for typing rheumatoid factors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
WO2010042904A2 (en) * 2008-10-10 2010-04-15 Trubion Pharmaceuticals, Inc. Tcr complex immunotherapeutics
CN102292352A (zh) * 2008-10-10 2011-12-21 新兴产品开发西雅图有限公司 Tcr复合物免疫治疗剂
CN103833855A (zh) * 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
CN103917557A (zh) * 2011-08-17 2014-07-09 葛兰素集团有限公司 具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体
CN105377894A (zh) * 2013-06-04 2016-03-02 瑞泽恩制药公司 以il-4r抑制剂治疗过敏症及强化过敏原特异性免疫治疗的方法
CN106573074A (zh) * 2014-06-02 2017-04-19 里珍纳龙药品有限公司 生物活性分子偶联物、试剂和制备方法及其治疗用途
WO2018091580A1 (en) * 2016-11-18 2018-05-24 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Drug Target Interference in Immunogenicity Assays: Recommendations and Mitigation Strategies;Zhandong Don Zhong et al.;《The AAPS Journal》;第19卷(第6期);第1564-1575页 *
Pre-existing Reactivity to an IgG4 Fc‑Epitope: Characterization and Mitigation of Interference in a Bridging Anti-drug Antibody Assay;Michael A. Partridge1 et al.;《The AAPS Journal》;第24卷(第78期);第1-12页 *

Also Published As

Publication number Publication date
AU2019302642A1 (en) 2021-02-25
EP3820891A1 (en) 2021-05-19
CN112543768A (zh) 2021-03-23
KR102938177B1 (ko) 2026-03-11
EA202190228A1 (ru) 2021-04-14
MX2021000239A (es) 2021-03-25
US12523659B2 (en) 2026-01-13
SG11202012835RA (en) 2021-01-28
AU2019302642B2 (en) 2025-10-30
US20200018754A1 (en) 2020-01-16
WO2020014358A1 (en) 2020-01-16
JP7665339B2 (ja) 2025-04-21
MY202673A (en) 2024-05-14
AR115730A1 (es) 2021-02-17
TW202428612A (zh) 2024-07-16
IL279803A (en) 2021-03-01
US11448651B2 (en) 2022-09-20
IL316308A (en) 2024-12-01
TWI838388B (zh) 2024-04-11
MX2025013509A (es) 2025-12-01
JP2021531245A (ja) 2021-11-18
CA3104873A1 (en) 2020-01-16
TW202021984A (zh) 2020-06-16
JP2025100662A (ja) 2025-07-03
US20230266333A1 (en) 2023-08-24
BR112020026784A2 (pt) 2021-03-30
KR20210030378A (ko) 2021-03-17

Similar Documents

Publication Publication Date Title
JP7442581B2 (ja) ヒトｉｌ－４受容体に対する高親和性ヒト抗体
RU2690675C2 (ru) Способы лечения или предотвращения астмы посредством введения антагониста il-4r
JP2025100662A (ja) 既存の相互作用を最小化する改変結合分子
CA3187315A1 (en) Treatment of idiopathic inflammatory myopathies
EA047574B1 (ru) Модификация связывающих молекул для минимизации уже существующих взаимодействий
EA040089B1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant